Last reviewed · How we verify
Intra-Operative Nausea and Vomiting — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Inapsine | DROPERIDOL | Rising | Dopamine-2 Receptor Antagonist [EPC] | D(2) dopamine receptor | 1970-01-01 | |
| Droleptan | Droleptan | Clinique Saint Jean, France | D(4) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2A |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Clinique Saint Jean, France · 1 drug in Intra-Operative Nausea and Vomiting
- Rising · 1 drug in Intra-Operative Nausea and Vomiting
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Intra-Operative Nausea and Vomiting:
- Intra-Operative Nausea and Vomiting treatment updates — RSS
- Intra-Operative Nausea and Vomiting treatment updates — Atom
- Intra-Operative Nausea and Vomiting treatment updates — JSON
Cite this brief
Drug Landscape (2026). Intra-Operative Nausea and Vomiting — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/intra-operative-nausea-and-vomiting. Accessed 2026-06-10.
Related
- Intra-Operative Nausea and Vomiting full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing